Annual report [Section 13 and 15(d), not S-K Item 405]

INTELLECTUAL PROPERTY LICENSING RIGHTS (Details Narrative)

v3.25.1
INTELLECTUAL PROPERTY LICENSING RIGHTS (Details Narrative) - USD ($)
1 Months Ended 12 Months Ended
Oct. 12, 2018
Dec. 31, 2024
Dec. 31, 2023
Intellectual Property [Member]      
Amortization expense   $ 1,179 $ 1,179
Accumulated amortization   $ 7,352  
Naltrexone Implant Formulation [Member] | Australia from Trinity Compound Solutions [Member]      
Patent acquired $ 15,200    
Estimated useful lives 13 years